For more than a decade, the International Myeloma Foundation has attended the American Society of Hematology (ASH) annual meeting, an exciting convergence of more than 30,000 health-care professionals from around the world. Explore this page to learn about the latest blood cancer research from the meeting, especially key clinical trials to advance the treatment and management of multiple myeloma
In this overview, IMF Chief Medical Officer Dr. Josesph Mikhael focuses on the latest research on health disparities in multiple myeloma care, culled from abstracts presented at the 64th American Society of Hematology Annual Meeting and Exposition.
Tune in as the IMF brings myeloma support group leaders and patients to the hybrid 64th American Society of Hematology (ASH) Annual Meeting, an exciting convergence of 10,000 health care professionals from around the world. Start following the IMF ASH team members now on social media as they ramp up to share the latest clinical updates in myeloma research, therapies, and practice strategies via Twitter (#ASH22 and #IMFASH22), Facebook, blogs, and videos.
Of the more than 3,000 abstracts presented at the 2022 ASH meeting, 1,041 were related to multiple myeloma. In this webinar, IMF Chairman of the Board Dr. Brian G.M. Durie highlights the top myeloma abstracts presented during the annual conference
At the upcoming IMWG Conference Series, “Making Sense of Treatment,” leading myeloma experts will discuss the latest myeloma news from the 64th ANNUAL American Society of Hematology Conference. December 2022
Quick 5 minute interviews from myeloma specialists at ASH on key abstracts, top 10 lists and summaries.
A symposium featuring discussion of patient case studies and key clinical trial data by renowned clinical experts providing their perspectives on recent advances in the treatment of multiple myeloma.
Post-ASH Key Opinion Leader Interviews supported by:
Pfizer, Sanofi, Janssen, BMS